BridgeBio Pharma, Inc.BBIO
| Dec 31,
2019 | Dec 31,
2020 | Dec 31,
2021 | Dec 31,
2022 | Dec 31,
2023 | Dec 31,
2024 |
|---|
| Revenue, net | 41 | 8 | 70 | 78 | 9 | 222 |
|---|
| Cost of revenue | - | - | 3 | - | 2 | 4 |
|---|
| Research and development | 210 | 337 | 451 | 399 | 456 | 506 |
|---|
| Selling, general and administrative | - | - | 192 | 143 | 151 | 289 |
|---|
| Restructuring Charges | - | - | - | 44 | 8 | 16 |
|---|
| Total operating costs and expenses | - | - | 646 | 590 | 617 | 815 |
|---|
| Loss from operations | -266 | -474 | -577 | -512 | -607 | -593 |
|---|
| Interest income | 9 | 4 | 1 | 8 | 18 | 17 |
|---|
| Interest expense, net | - | - | - | - | - | 99 |
|---|
| Deconsolidation, Gain (Loss), Amount | - | - | - | - | - | 178 |
|---|
| Loss on extinguishment of debt | - | - | -3 | - | - | -27 |
|---|
| Net loss from equity method investments | -21 | - | - | - | - | -31 |
|---|
| Gain from sale of priority review voucher, net | - | - | - | 108 | - | - |
|---|
| Other income (expense), net | - | 2 | 36 | -7 | 17 | 12 |
|---|
| Total other income (expense), net | -22 | -31 | -10 | 28 | -46 | 51 |
|---|
| Loss before income taxes | - | - | - | - | - | -542 |
|---|
| Income tax expense | - | - | - | - | - | 1 |
|---|
| Net loss | -289 | -505 | -586 | -485 | -653 | -543 |
|---|
| Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests | -28 | -57 | -24 | -3 | -10 | -8 |
|---|
| Net loss attributable to common stockholders of BridgeBio | -261 | -449 | -563 | -481 | -643 | -536 |
|---|
| Earnings Per Share, Basic | - | - | - | -3.26 | -3.95 | -2.88 |
|---|
| Earnings Per Share, Diluted | - | - | - | -3.26 | -3.95 | -2.88 |
|---|